MedPath

Non-IRA Functional Evaluation With AccuFFRangio in NSTE-ACS

Not Applicable
Conditions
Non ST Segment Elevation Acute Coronary Syndrome
Coronary Artery Disease
Percutaneous Coronary Intervention
Registration Number
NCT05202041
Lead Sponsor
Wuhan Asia Heart Hospital
Brief Summary

This is a prospective, single-center clinical trial. AccuFFRangio (ArteryFlow Technology Co., Ltd., Hangzhou, China) is a novel method for evaluating the functional significance of coronary stenosis by computing the pressure in the vessel based on angiographic images. The purpose of this study is to investigate the diagnostic performance and prognostic ability of AccuFFRangio for non-IRA in NSTE-ACS patients.

Detailed Description

Not available

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
500
Inclusion Criteria
  • 18 Years and older
  • Non-ST-segment elevation acute coronary syndrome patients with at least 1 non-IRA
  • Diameter stenosis of 50%-90% by visual estimate
  • Reference vessel size > 2 mm in stenotic segment by visual estimate
Exclusion Criteria
  • LVEF ≤ 40%
  • eGFR < 60 mL/min
  • Allergy to contrast media, adenosine
  • Prior CABG

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
Vessel-oriented composite endpoints (VOCEs)1 year

Composite of vessel-related cardiovascular death, vessel-related myocardial infarction, and ischemia-driven target vessel revascularization.

Post-PCI AccuFFRangio1 year

AccuFFRangio limits to yield no VOCEs.

Secondary Outcome Measures
NameTimeMethod
Cost analysis1 year

Cost savings of AccuFFRangio-guided strategy.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.